Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 17 de 17
Filter
Add more filters










Publication year range
1.
Exp Dermatol ; 21(7): 520-5, 2012 Jul.
Article in English | MEDLINE | ID: mdl-22716247

ABSTRACT

Actinic keratosis (AK) is characterized by high prevalence and the risk to proceed to squamous cell carcinoma (SCC). Cyclooxygenase-2 (COX-2)-mediated prostaglandin E2 (PGE (2) ) synthesis has been reported in AK and SCC, and the COX inhibitor diclofenac in hyaluronic acid (diclofenac/HA) was approved for AK therapy. Its mode of action, however, remained to be unravelled. In the present study, diclofenac resulted in reduced PGE (2) levels in apoptosis-sensitive cutaneous SCC cell lines (SCL-II, SCC-12, SCC-13) whereas no PGE (2) and no COX-2 expression was detectable in a SCC cell line resistant to apoptosis induction (SCL-I). Activation of mitochondrial apoptosis pathways was evident in SCC cells owing to loss of the mitochondrial membrane potential and release of the mitochondrial factors cytochrome c and apoptosis-inducing factor. Characteristic proapoptotic changes at the level of Bcl-2 proteins occurred in sensitive cells, as upregulation of Bad and downregulation of Mcl-1 and Bcl-w. In contrast, Bad was already high, and Mcl-1 and Bcl-w were already low in resistant SCL-I, even without treatment, which may be explained by the lack of PGE (2) . An antiapoptotic downregulation of proapoptotic Bcl-2 proteins Noxa and Puma was, however, also seen in SCL-I, suggesting here pathways independent of COX-2. The regulations of Mcl-1 and Bad were also reproduced in SCC cells by the more selective COX-2 inhibitor celecoxib, thus further underlining the specific role of COX-2. The findings illuminate the mode of action of diclofenac/HA in SCC cells as well as principles of their resistance, which may allow further adaptation and improvement of the new therapy.


Subject(s)
Cyclooxygenase 2/metabolism , Cyclooxygenase Inhibitors/pharmacology , Diclofenac/pharmacology , Dinoprostone/metabolism , Mitochondria/metabolism , Apoptosis/drug effects , Apoptosis Inducing Factor/metabolism , Apoptosis Regulatory Proteins/drug effects , Apoptosis Regulatory Proteins/metabolism , Carcinoma, Squamous Cell , Celecoxib , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cyclooxygenase 2/drug effects , Cytochromes c/metabolism , Down-Regulation , Humans , Hyaluronic Acid/pharmacology , Myeloid Cell Leukemia Sequence 1 Protein , Proto-Oncogene Proteins/drug effects , Proto-Oncogene Proteins/metabolism , Proto-Oncogene Proteins c-bcl-2/drug effects , Proto-Oncogene Proteins c-bcl-2/metabolism , Pyrazoles/pharmacology , Skin Neoplasms , Sulfonamides/pharmacology , Up-Regulation , bcl-Associated Death Protein/drug effects , bcl-Associated Death Protein/metabolism
2.
J Invest Dermatol ; 132(9): 2263-74, 2012 Sep.
Article in English | MEDLINE | ID: mdl-22551975

ABSTRACT

Suberoylanilide hydroxamic acid (SAHA) has been approved for the treatment of cutaneous T-cell lymphoma (CTCL), but its mode of action remained largely elusive. As shown here in four CTCL cell lines, loss of cell viability correlated with significant time- and dose-dependent induction of apoptosis, whereas cytotoxicity was less pronounced. Both extrinsic and intrinsic apoptosis pathways were activated, as seen by processing of initiator caspases 8 and 9, loss of mitochondrial membrane potential, and cytochrome c release. Characteristically, antiapoptotic mediators such as Mcl-1, XIAP, survivin, and c-FLIP were downregulated. Consistent with its critical function, c-FLIP overexpression resulted in a significant decrease of SAHA-mediated apoptosis. Enhanced sensitivity to TRAIL (TNF-related apoptosis-inducing ligand) and enhanced TRAIL signaling was seen in CTCL cell lines with high sensitivity, whereas cell lines with moderate response were characterized by downregulation of TRAIL-R2 and weaker TRAIL expression. Comparable proapoptotic responses to SAHA and to the combination with TRAIL were seen in ex vivo tumor T cells of CTCL patients. Thus, activation of extrinsic apoptosis pathways, related to c-FLIP downregulation and enhanced TRAIL signaling, appeared as characteristic for CTCL cell responsiveness to SAHA. An improved understanding of the pathways may facilitate its targeted use and the selection of suitable combinations.


Subject(s)
Antineoplastic Agents/pharmacology , CASP8 and FADD-Like Apoptosis Regulating Protein/antagonists & inhibitors , Hydroxamic Acids/pharmacology , Lymphoma, T-Cell, Cutaneous/metabolism , Skin Neoplasms/metabolism , TNF-Related Apoptosis-Inducing Ligand/metabolism , Aged , Aged, 80 and over , Down-Regulation/drug effects , Female , Humans , Inhibitor of Apoptosis Proteins/metabolism , Male , Middle Aged , Signal Transduction/drug effects , Tumor Cells, Cultured , Up-Regulation/drug effects , Vorinostat
3.
Hum Gene Ther ; 22(4): 405-17, 2011 Apr.
Article in English | MEDLINE | ID: mdl-20977303

ABSTRACT

High mortality and therapy resistance of melanoma demand the development of new strategies, and overcoming apoptosis deficiency appears as particularly promising. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has shown high potential for apoptosis induction in melanoma cells and may be applicable for gene therapy because of its selective impact on tumor cells. We have constructed a conditional replication-competent adenoviral vector with TRAIL controlled by a tetracycline-inducible promoter (AdV-TRAIL). A variant E1A protein and the lack of E1B aimed at the restriction of viral replication to tumor cells. In particular, the replication gene E1A is controlled by a tyrosinase promoter with high selectivity for melanoma cells. AdV-TRAIL mediated strong expression of E1A and doxycycline-dependent induction of TRAIL selectively in melanoma cells, which resulted in tumor cell lysis and induction of apoptosis. In contrast, non-melanoma cells and normal human melanocytes appeared to be protected. Comparison of the AdV-TRAIL approach with a comparable CD95L vector revealed similar efficacy in vitro. In mouse xenotransplantation models, AdV-TRAIL demonstrated its activity by significant melanoma growth reduction. Melanoma cell killing by AdV-TRAIL was further improved in vitro by combinations with chemotherapeutics. We demonstrate that melanoma cells may be efficiently targeted by TRAIL-based gene therapy, and resistance may be overcome by combined chemotherapy.


Subject(s)
Adenoviridae , Apoptosis , Genetic Therapy , Genetic Vectors , Melanoma/therapy , TNF-Related Apoptosis-Inducing Ligand/metabolism , Virus Replication/genetics , Adenoviridae/genetics , Adenoviridae/metabolism , Adenovirus E1A Proteins/metabolism , Animals , Apoptosis/genetics , Cell Line, Tumor , Cell Proliferation , Cell Survival/genetics , Fas Ligand Protein/genetics , Fas Ligand Protein/metabolism , Female , Gene Expression Regulation/genetics , Genetic Vectors/genetics , HEK293 Cells , Hep G2 Cells , Humans , Melanoma/metabolism , Mice , Mice, Inbred BALB C , Mice, Nude , TNF-Related Apoptosis-Inducing Ligand/genetics , Xenograft Model Antitumor Assays
4.
J Invest Dermatol ; 130(8): 2098-109, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20237495

ABSTRACT

Actinic keratosis (AK) occurs on sun-exposed skin and may progress to invasive squamous cell carcinoma (SCC). As for its topical treatment, diclofenac/hyaluronic acid (HA) has been recently approved. The NSAID diclofenac is an inhibitor of COX-2; however, its mode of action in cutaneous epithelial cancer cells is largely unknown. Here, the effects of diclofenac/HA were investigated in relation to death ligand-mediated apoptosis (TNF-alpha, TRAIL, and CD95 activation). Whereas diclofenac/HA only moderately induced apoptosis by itself, it resulted in pronounced enhancement of death ligand-mediated apoptosis in sensitive SCC cell lines (3/4). Apoptosis was associated with activation of initiator caspases of the extrinsic pathway (caspase-8/caspase-10). Furthermore, death ligand and diclofenac/HA-mediated apoptosis were blocked by the same caspase inhibitors, indicating related pathways. The proapoptotic effects of diclofenac/HA appeared independent of the p53 pathway. Also, upregulation of death receptors appeared less important; however, strong downregulation of c-FLIP isoforms was seen after diclofenac/HA treatment. The crucial role of c-FLIP was proven through overexpression and knockdown experiments. Thus, induction of apoptosis appears to be highly characteristic of the mode of action of diclofenac/HA, and the therapeutic effect may be related to sensitization of neoplastic keratinocytes for death ligand-induced apoptosis.


Subject(s)
Apoptosis/drug effects , CASP8 and FADD-Like Apoptosis Regulating Protein/metabolism , Carcinoma, Squamous Cell/drug therapy , Diclofenac/pharmacology , Hyaluronic Acid/pharmacology , Skin Neoplasms/drug therapy , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Apoptosis/physiology , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/pathology , Caspases/metabolism , Cell Line, Transformed , Cell Line, Tumor , Down-Regulation/drug effects , Down-Regulation/physiology , Humans , Jurkat Cells , Keratinocytes/drug effects , Keratinocytes/metabolism , Keratinocytes/pathology , Ligands , Skin Neoplasms/metabolism , Skin Neoplasms/pathology , Tumor Suppressor Protein p53/metabolism
5.
Exp Dermatol ; 19(8): e56-66, 2010 Aug.
Article in English | MEDLINE | ID: mdl-19725869

ABSTRACT

The high mortality of melanoma demands the development of new strategies, and gene therapy may be considered provided improvements in efficacy and selectivity. Overexpression of the death ligand CD95L/FasL has been shown in previous studies as highly effective for apoptosis induction in melanoma cells. For efficient and selective targeting of melanoma, a conditional replication-competent adenoviral vector was constructed (Ad5-FFE-02), which drives CD95L expression by a tetracycline-inducible promoter. For restricting its replication to melanoma cells, the adenoviral E1A gene is controlled by a tyrosinase-derived promoter. Furthermore, adenoviral E1B was deleted and a mutated E1A was used to preferentially support replication in tumor cells. Proving its high selectivity and efficiency, strong expression of E1A and doxycycline-dependent induction of CD95L were characteristic for tyrosinase-positive melanoma cells after Ad5-FFE-02 transduction, whereas absent in non-melanoma cell lines. Importantly, Ad5-FFE-02-mediated cell lysis was restricted to melanoma cells, and induction of apoptosis was found only in tyrosinase and CD95 expressing cells. Finally, the combination of adenoviral replication and CD95L-mediated apoptosis resulted in an enhanced repression of melanoma cell growth. This new adenoviral vector may provide a basis for an efficient targeting of melanoma.


Subject(s)
Adenoviridae/genetics , Apoptosis , Fas Ligand Protein/genetics , Genetic Therapy , Melanoma/therapy , Skin Neoplasms/therapy , Virus Replication/physiology , Adenoviridae/physiology , Adenovirus E1A Proteins/metabolism , Cell Line, Tumor , Doxycycline/pharmacology , Fas Ligand Protein/metabolism , Gene Expression Regulation, Neoplastic/drug effects , Gene Expression Regulation, Viral/drug effects , Genetic Vectors , Humans , Melanoma/metabolism , Melanoma/pathology , Plasmids , Skin Neoplasms/metabolism , Skin Neoplasms/pathology
6.
Exp Dermatol ; 17(1): 1-11, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18095940

ABSTRACT

In the last decades melanoma incidence has been increasing worldwide, while mortality remained on a high level. Until now, there is no suitable therapy for metastasized melanoma, which could lead to a significant increase in overall survival. Apoptosis deficiency is supposed to be a critical factor for therapy resistance, and previous work has characterized the basic mechanisms of apoptosis regulation in melanoma. Genes and strategies suitable for efficient induction of apoptosis in melanoma cells were identified, which are based on proapoptotic Bcl-2 proteins (Bcl-x(S), Bcl-x(AK), Bik/Nbk and Bax) as well as on tumor necrosis factor (TNF)-related death ligands (CD95L/Fas ligand and TNF-related apoptosis-inducing ligand, TRAIL). Proapoptotic genes may be employed in improved gene therapeutic strategies, based on conditional oncolytic adenoviral vectors.


Subject(s)
Apoptosis/genetics , Genetic Therapy/methods , Melanoma/therapy , Skin Neoplasms/therapy , Adenoviridae/genetics , Drug Resistance, Neoplasm , Genetic Vectors/genetics , Humans , Melanoma/genetics , Skin Neoplasms/genetics
7.
Drug Resist Updat ; 10(6): 218-34, 2007 Dec.
Article in English | MEDLINE | ID: mdl-18054518

ABSTRACT

The increased incidence of malignant melanoma in the last decades, its high mortality and pronounced therapy resistance pose an enormous challenge. Important therapeutic targets for melanoma are the induction of apoptosis and suppression of survival pathways. Preclinical studies have demonstrated the efficacy of pro-apoptotic Bcl-2 proteins and of death receptor ligands to trigger apoptosis in melanoma cells. In the clinical setting, BH3 domain mimics and death receptor agonists are therefore considered as promising, specific novel treatments to add to the conventional pro-apoptotic strategies such as chemo- or radiotherapy. However, constitutively activated survival pathways, in particular the mitogen-activated protein kinases, protein kinase B/Akt and nuclear factor (NF)-kappaB, all may work in concert to prevent effective therapy. Thus, selective biologicals developed with the aim to inhibit pro-survival signaling are currently tested in melanoma. For highly therapy-resistant tumors such as melanoma, development of novel drug combinations will be essential, and combinations of survival inhibitors and pro-apoptotic mediators appear most promising. The challenge of the near future will be to make a rational choice of the multiple possible combinations and protocols. This review gives a critical overview of proteins involved in melanoma chemoresistance, which are targets for current drug development leading to the best choice for future trials.


Subject(s)
Antineoplastic Agents/therapeutic use , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Apoptosis/drug effects , Melanoma/drug therapy , Signal Transduction/drug effects , Animals , Antineoplastic Agents/pharmacology , Antineoplastic Combined Chemotherapy Protocols/pharmacology , Apoptosis/genetics , Caspases/metabolism , Cell Survival/drug effects , Cysteine Proteinase Inhibitors/therapeutic use , Drug Resistance, Neoplasm , Gene Expression Regulation, Neoplastic , Humans , Intracellular Signaling Peptides and Proteins/metabolism , Melanoma/enzymology , Melanoma/genetics , Melanoma/metabolism , Melanoma/pathology , Mutation , Protein Kinase Inhibitors/therapeutic use , Proto-Oncogene Proteins c-bcl-2/antagonists & inhibitors , Proto-Oncogene Proteins c-bcl-2/metabolism , Receptors, Death Domain/agonists , Receptors, Death Domain/metabolism , Signal Transduction/genetics , Tumor Suppressor Protein p53/metabolism
8.
J Invest Dermatol ; 127(10): 2425-37, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17495957

ABSTRACT

Control of apoptosis via death ligands plays a basic role for lymphocyte homeostasis and lymphoma development. In this study, cutaneous T-cell lymphoma (CTCL) cell lines revealed pronounced resistance to death ligands as compared to cell lines of T-cell acute lymphoblastic leukemia (T-ALL). The proapoptotic activity of tumor necrosis factor (TNF)-alpha was blocked, sensitivity to TNF-related apoptosis-inducing ligand was significantly reduced, and 1/4 CTCL cell lines was resistant to CD95 activation. In parallel, there was no activation of effector caspase-3 and initiator caspase-8 in nonresponsive CTCL cells, whereas caspase-10 was cleaved selectively in sensitive CTCL cells. No indication for a responsibility of typical downstream regulators of apoptosis was obtained, but loss of CD95 was found in 1/4, loss of TNF-R1 in 3/4, loss of caspase-10 in 2/4, loss of Bid in 1/4, and overexpression of cellular flice inhibitory protein was found in 4/4 CTCL cell lines. This clearly indicates an inhibition of apoptosis early in the extrinsic cascade, namely at the formation of the death-inducing signaling complex. Parallels with regard to expression of apoptosis regulators were seen in peripheral blood mononuclear cells and biopsies of CTCL patients. This study may indicate defects in apoptosis in CTCL and may help to guide CTCL therapy.


Subject(s)
Apoptosis/physiology , Lymphoma, T-Cell, Cutaneous/pathology , Receptors, Death Domain/antagonists & inhibitors , Signal Transduction/physiology , Skin Neoplasms/pathology , Aged , Apoptosis/drug effects , BH3 Interacting Domain Death Agonist Protein/physiology , CASP8 and FADD-Like Apoptosis Regulating Protein/physiology , Caspase 10/physiology , Cell Line, Tumor , Female , Humans , Leukemia-Lymphoma, Adult T-Cell/pathology , Leukemia-Lymphoma, Adult T-Cell/physiopathology , Lymphoma, T-Cell, Cutaneous/physiopathology , Male , Middle Aged , Receptors, Death Domain/physiology , Skin Neoplasms/physiopathology , TNF-Related Apoptosis-Inducing Ligand/antagonists & inhibitors , TNF-Related Apoptosis-Inducing Ligand/physiology , Tumor Necrosis Factor-alpha/antagonists & inhibitors , Tumor Necrosis Factor-alpha/physiology , fas Receptor/physiology
9.
J Invest Dermatol ; 126(6): 1366-71, 2006 Jun.
Article in English | MEDLINE | ID: mdl-16528364

ABSTRACT

Prognosis of primary melanoma is presently based on morphological parameters, mainly tumor thickness. However, more reliable prognostic markers are needed that allow a better stratification of patients, especially with regard to therapeutic options. Here, a retrospective study was performed on patients with primary superficial-spreading melanoma (SSM, n=44) or nodular melanoma (n=16) of 1.5-4 mm thickness. Thirty patients had survived the follow-up of 10 years, whereas the other 30 patients developed metastases. Tumor sections were analyzed by immunohistochemistry for the expression of regulators of the cell cycle (p21; retinoblastoma protein (pRb)), of the intrinsic or extrinsic proapoptotic pathways (p53; murine double minute gene 2 protein; tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-R1/DR4; TRAIL-R2/DR5) and of Bcl-2-related proteins (Bcl-2, Mcl-1, Bax, Bak, Bok), which regulate the common mitochondrial apoptotic pathway. In SSM, decrease of Bax and Bak was significantly correlated with a poor prognosis: high Bax was associated with 10-year survival rates of 68%, whereas low Bax resulted in only 26% survival, and high Bak was associated with 10-year survival rates of 62%, whereas low Bak resulted in only 10% survival. Regulators of apoptosis may therefore candidate for independent prognostic markers for primary melanomas. The study underlines the particular role of the mitochondrial apoptosis pathway and of proapoptotic Bcl-2-related proteins for melanoma progression.


Subject(s)
Apoptosis Regulatory Proteins/analysis , Biomarkers, Tumor/analysis , Melanoma/diagnosis , Skin Neoplasms/diagnosis , bcl-2 Homologous Antagonist-Killer Protein/analysis , bcl-2-Associated X Protein/analysis , Aged , Apoptosis , Female , Humans , Male , Melanoma/pathology , Middle Aged , Prognosis , Protein Structure, Tertiary , Skin Neoplasms/pathology
10.
J Invest Dermatol ; 125(5): 1010-9, 2005 Nov.
Article in English | MEDLINE | ID: mdl-16297203

ABSTRACT

Therapy resistance is crucial for the high mortality of melanoma. The death ligand tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) bears high potential as a new anticancer agent, as binding to the death receptors TRAIL receptor 1/death receptor 4 (TRAIL-R1/DR4) or TRAIL receptor 2/death receptor 5 (TRAIL-R2/DR5) triggers apoptosis in most cancer cells. For melanoma, however, only a weak responsiveness of primary cultures was reported, and in particular the role of DR4 was neglected. For evaluating melanoma susceptibility, we studied the functionality of DR4 and DR5 in melanoma cells as well as their expression in vivo. DR5 was consistently expressed in melanoma cell lines, whereas DR4 was found in only 2/7 cell lines. High sensitivity to TRAIL-induced apoptosis was characteristic for DR4-positive melanoma cells, whereas DR4-negative cells showed less and delayed response or were resistant. The use of selective DR4/DR5 blocking antibodies unequivocally proved the prevalent role of DR4 in those melanoma cells, where it was expressed. The significance of these data for the in vivo situation was finally evaluated by immunohistochemistry, which proved pronounced expression of DR4 as well as of DR5 in melanoma primary tumors. Thus, DR4 expression in vivo and the high efficiency of DR4-mediated apoptosis may suggest reassessment of the suitability of TRAIL and especially of DR4-based strategies for melanoma treatment.


Subject(s)
Antineoplastic Agents/pharmacology , Apoptosis Regulatory Proteins/pharmacology , Melanoma/metabolism , Membrane Glycoproteins/pharmacology , Receptors, Tumor Necrosis Factor/metabolism , Skin Neoplasms/metabolism , Tumor Necrosis Factor-alpha/pharmacology , Antibodies, Blocking/pharmacology , Apoptosis , Cell Line, Tumor , Drug Resistance, Neoplasm , Humans , Melanoma/chemistry , Melanoma/pathology , Receptors, TNF-Related Apoptosis-Inducing Ligand , Receptors, Tumor Necrosis Factor/analysis , Receptors, Tumor Necrosis Factor/antagonists & inhibitors , Skin Neoplasms/chemistry , Skin Neoplasms/pathology , TNF-Related Apoptosis-Inducing Ligand
11.
Oncogene ; 24(49): 7369-80, 2005 Nov 10.
Article in English | MEDLINE | ID: mdl-16007125

ABSTRACT

The proapoptotic BH3-only protein natural born killer / Bcl-2 interacting killer (Nbk/Bik) has been described to inhibit Bcl-2 and Bcl-xL, thereby supporting the death promoting ability of Bax. In order to evaluate its function in melanoma, we investigated the response after Nbk/Bik overexpression in cultured human melanoma cells and in a melanoma mouse model. Untransfected melanoma cell lines expressed Nbk/Bik only weakly at the mRNA and protein level. Conditional expression of Nbk/Bik by applying the inducible tetracycline-responsive expression system triggered apoptosis and enhanced sensitivity to proapoptotic stimuli as to agonistic CD95 activation and to chemotherapeutics etoposide, doxorubicin and pamidronate. For investigating the effects of Nbk/Bik in vivo, stably transfected melanoma cells were subcutaneously injected into nude mice. Significantly delayed tumor growth was the result when mice received doxycycline for induction of Nbk/Bik expression. By investigating the mechanism of Nbk/Bik-induced cell death, typical hallmarks of apoptosis such as DNA fragmentation and chromatin condensation were seen after induction. Interestingly, no indications for cytochrome c release and caspase processing were found, and selective caspase inhibition remained without effect. These data indicate the high potential of Nbk/Bik in regulating apoptosis in melanoma by a caspase-independent pathway and may corroborate the potency of novel antimelanoma strategies based on activation of BH3-only proteins such as Nbk/Bik.


Subject(s)
Apoptosis , Caspases/metabolism , Drug Resistance, Neoplasm , Gene Expression Regulation, Neoplastic , Melanoma/metabolism , bcl-2 Homologous Antagonist-Killer Protein/metabolism , Animals , Anti-Inflammatory Agents/pharmacology , Antibiotics, Antineoplastic/pharmacology , Antineoplastic Agents, Phytogenic/pharmacology , Chromatin/metabolism , Cytochromes c/metabolism , Diphosphonates/pharmacology , Doxorubicin/pharmacology , Etoposide/pharmacology , Female , Flow Cytometry , Humans , In Situ Nick-End Labeling , Injections, Subcutaneous , Melanoma/drug therapy , Melanoma/pathology , Mice , Mice, Inbred BALB C , Mice, Nude , Pamidronate , Protein Synthesis Inhibitors/pharmacology , Proto-Oncogene Proteins c-bcl-2/metabolism , Skin/metabolism , Tetracycline/pharmacology , Tumor Cells, Cultured , bcl-2-Associated X Protein/metabolism , fas Receptor/metabolism
12.
J Invest Dermatol ; 124(1): 221-8, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15654977

ABSTRACT

Induction of apoptosis has been demonstrated previously by overexpression of CD95 ligand (CD95L) in cultured human melanoma cells. For in vivo approaches based on CD95L, however, targeted expression is a prerequisite and tyrosinase promoters have been considered for selection. Luciferase reporter gene assays performed for a representative panel of melanoma cell lines characterized by strong (SK-Mel-19), moderate (SK-Mel-13, MeWo), weak (A-375), and missing expression (M-5) of endogenous tyrosinase revealed high tyrosinase promoter activities in SK-Mel-19, SK-Mel-13, and MeWo, but only weak activities in A-375 and M-5 as well as in non-melanoma cell lines. After transfection of a CMV promoter CD95L expression construct, melanoma cells were found highly sensitive, as compared with non-melanoma cells. By applying a tyrosinase promoter CD95L construct, apoptosis was selectively induced in SK-Mel-19, SK-Mel-13, MeWo as well as in A-375, which was characterized by high CD95 surface expression and high sensitivity to agonistic CD95 activation. M5 and non-melanoma cell lines remained uninfluenced. Also, resistance to agonistic CD95 activation seen in MeWo characterized by weak CD95 surface expression was overcome by overexpression of CD95L. Our investigations provide evidence that tyrosinase promoter CD95L constructs may be of value for selective induction of apoptosis in therapeutic strategies for melanoma.


Subject(s)
Apoptosis/physiology , Melanoma , Membrane Glycoproteins/genetics , Monophenol Monooxygenase/genetics , Skin Neoplasms , Caspases/metabolism , Cell Line, Tumor , DNA-Binding Proteins/genetics , Fas Ligand Protein , Gene Expression Regulation, Neoplastic , Genetic Therapy/methods , Humans , Luciferases/genetics , Membrane Glycoproteins/metabolism , Microphthalmia-Associated Transcription Factor , Promoter Regions, Genetic/genetics , Transcription Factors/genetics
13.
Oncogene ; 22(57): 9131-41, 2003 Dec 11.
Article in English | MEDLINE | ID: mdl-14668794

ABSTRACT

The significance of CD95/Fas ligand expression by melanoma cells has remained a controversial matter in recent years. On the other hand, CD95 activation may represent a powerful tool for eliminating tumor cells. Here, we demonstrate expression of CD95 in 15/17 human melanoma cell lines analysed, but complete lack of CD95 ligand (CD95L). Overexpression of CD95 in a tetracycline-inducible expression system enhanced melanoma cell sensitivity to CD95 ligation but was unable to trigger apoptosis by itself. In clear contrast, all melanoma cells tested responded with increased apoptosis to conditional expression of CD95L (2-10-fold), both after transient and after stable transfection. Activation of caspase-8, Bid cleavage, cytochrome c release and caspase-3 activation followed after CD95L induction indicating a functional CD95-signaling cascade. CD95L was also able to enhance the proapoptotic effect of chemotherapeutics applied in parallel. Nude mouse experiments revealed that tumorigenicity was lost when melanoma xenografts were triggered to express CD95L. In addition, further progression of pre-existing melanomas was inhibited and even regression was seen after induction of CD95L expression. Due to these data, transfection of CD95L proofs as a highly efficient tool against melanoma cells in vitro and in vivo, and targeted expression of CD95L may thus represent a suitable strategy for melanoma therapy.


Subject(s)
Apoptosis/physiology , Melanoma/pathology , Membrane Glycoproteins/genetics , Transplantation, Heterologous/pathology , fas Receptor/physiology , Animals , Antigens, Surface/immunology , Cell Division , Cells, Cultured , Fas Ligand Protein , Gene Expression Regulation/immunology , Humans , Male , Melanocytes/cytology , Membrane Glycoproteins/immunology , Mice , Mice, Nude , RNA, Messenger/genetics , Recombinant Proteins/immunology , Transfection , Tumor Cells, Cultured
14.
FEBS Lett ; 553(3): 250-6, 2003 Oct 23.
Article in English | MEDLINE | ID: mdl-14572633

ABSTRACT

The Bcl-2-related proteins Bcl-X(L) and Bcl-X(S) represent alternative splice products and exert opposite activities in the control of apoptosis, but their significance for melanoma is not yet clear. Applying the tetracycline-inducible expression system Tet-On, we found overexpression of Bcl-X(S) by itself sufficient to induce apoptosis in vitro in stably transfected human melanoma cell lines. Combination with proapoptotic agents such as etoposide, pamidronate, and ceramide resulted in additive proapoptotic effects, whereas Bcl-X(L) protected from apoptosis caused via CD95/Fas stimulation. In nude mice growth of melanoma xenotransplants derived from stably transfected cells was significantly reduced after induction of Bcl-X(S) by doxycycline. Our results indicate that Bcl-X proteins are of major importance for control of apoptosis in malignant melanoma.


Subject(s)
Apoptosis/physiology , Melanoma/metabolism , Proto-Oncogene Proteins c-bcl-2/physiology , Animals , Apoptosis/drug effects , Cell Nucleus/ultrastructure , Chromatin/ultrastructure , Clone Cells , Doxycycline/pharmacology , Female , Humans , Melanocytes/cytology , Melanocytes/metabolism , Melanoma/genetics , Melanoma/pathology , Mice , Mice, Inbred BALB C , Mice, Nude , Proto-Oncogene Proteins c-bcl-2/genetics , Proto-Oncogene Proteins c-bcl-2/metabolism , Transfection , Tumor Cells, Cultured , Xenograft Model Antitumor Assays , bcl-X Protein , fas Receptor/pharmacology
15.
Article in English | MEDLINE | ID: mdl-12239426

ABSTRACT

The proapoptotic potential of tumor necrosis factor-alpha (TNF-alpha) has been demonstrated for various cell types, whereas nuclear factor-kappaB (NF-kappaB) is known to support the transcription of prosurvival genes. In the present study, investigation of normal human melanocytes revealed induction of apoptosis after TNF-alpha treatment (100 U/ml) in only 3 out of 11 cultures analyzed, whereas 8 cultures remained largely resistant. In sensitive cultures, NF-kappaB binding activity was found increased after TNF-alpha treatment; apoptosis-resistant cells were characterized by relatively high basic NF-kappaB binding activities and did not show NF-kappaB activation after TNF-alpha treatment. Inhibition of NF-kappaB by a specific inhibitor, Bay-11, either induced apoptosis itself or resistant melanocyte cultures became sensitive to TNF-alpha treatment. No correlation was found between apoptosis sensitivity and the expression of TNF receptor-1 or the expression of Bax, Bcl-2 and Bcl-X(L). A strong correlation, however, was found regarding the pigmentation degree, as high pigmentation correlated with apoptosis resistance and sensitive melanocyte cultures were weakly pigmented. These data may indicate that in cultured melanocytes, high levels of melanogenesis lead to an increase in oxidative stress which itself causes NF-kappaB activation. NF-kappaB mediates the transcription of antiapoptotic factors which may block TNF-alpha-induced apoptosis at early steps of the signal cascade.


Subject(s)
Apoptosis/drug effects , Melanocytes/drug effects , NF-kappa B/physiology , Tumor Necrosis Factor-alpha/pharmacology , Animals , Apoptosis/physiology , Cattle , Cell Division/drug effects , Cell Division/physiology , Cells, Cultured , Humans , Male , Melanocytes/cytology , Melanocytes/metabolism , NF-kappa B/antagonists & inhibitors , Signal Transduction/drug effects , Signal Transduction/physiology , Skin Pigmentation/drug effects , Skin Pigmentation/physiology
16.
J Invest Dermatol ; 119(3): 549-55, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12230494

ABSTRACT

Normal human melanocytes respond to endothelin-1 with induced proliferation and differentiation. Whereas in cultured melanoma cells the predominant endothelin receptor, ET(B)-R, is consistently downregulated, ET(B)-R upregulation was recently reported for melanoma tumors. Contrary to the pro-survival activity described for endothelin in vascular cells, a proapoptotic activity of endothelin-1 has been reported for melanoma cells, in previous studies. We therefore investigated the role of endothelin for melanoma cells with respect to apoptosis and proliferation. Treatment with 10 nM endothelin-1 was a strong mitogenic signal for normal human melanocytes, which responded with a 4-6-fold increase of thymidine incorporation, whereas the response was only 1.2-fold for SK-Mel-19, the melanoma cell line characterized by the highest ET(B)-R expression, and it was even less in other cell lines. Determination of the apoptotic rates revealed that endothelin-1 significantly reduced basic apoptotic rates to 75% both in SK-Mel-19 and in normal melanocytes. After cell synchronization, an antiapoptotic effect of endothelin-1 was seen in five of seven cell lines investigated. In the cell line Bro, which showed no response and which lacks ET(B)-R expression, responsibility could be restored by overexpression of ET(B)-R after stable transfection, indicating that the effectors of the endothelin-1 signal cascade were active in these cells, and that the antiapoptotic effect of endothelin-1 is mediated in a receptor-specific way. This antiapoptotic activity of endothelin for melanoma cells combined with upregulation of endothelin receptors in the tumor may be a crucial step for melanoma progression.


Subject(s)
Apoptosis/drug effects , Endothelin-1/pharmacology , Melanocytes/cytology , Melanoma , Skin Neoplasms , Apoptosis/physiology , Cell Division/drug effects , Cell Division/physiology , Down-Regulation/physiology , Endothelin-1/metabolism , Gene Expression Regulation, Neoplastic , Humans , Melanocytes/drug effects , Melanocytes/metabolism , Receptor, Endothelin B , Receptors, Endothelin/genetics , Receptors, Endothelin/metabolism , Transfection , Tumor Cells, Cultured
17.
J Invest Dermatol ; 118(6): 1019-25, 2002 Jun.
Article in English | MEDLINE | ID: mdl-12060397

ABSTRACT

Nitric oxide is a gaseous messenger involved in the regulation of several physiologic processes in various cell types, including skin cells. Three different nitric oxide synthases (neuronal nitric oxide synthase, endothelial nitric oxide synthase, inducible nitric oxide synthase) have been identified in human cells. For inducible nitric oxide synthase, an inducibility by cytokines and lipopolysaccharides have been found. For murine melanoma cells, a connection between elevated levels of nitric oxide after inducible nitric oxide synthase induction and consequent apoptosis had been described. By northern analysis, we detected inducible nitric oxide synthase mRNA in four of 15 human melanoma cell lines cultured without inducible nitric oxide synthase inducing cytokines. Induction of inducible nitric oxide synthase mRNA by tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharides was seen in normal human melanocytes but not in melanoma cell lines. In accordance, inducible nitric oxide synthase protein expression was clearly inducible in cultures of normal melanocytes, whereas in six melanoma cell lines investigated, inducible nitric oxide synthase was found weakly expressed already before treatment with tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharides, and its expression was not inducible. The apoptotic rates both in normal melanocytes and in two melanoma cell lines (SK-Mel-19 and O-Mel-2) were increased by treatment with tumor necrosis factor-alpha, interferon-gamma, and lipopolysaccharides; however, these effects could not be prevented by the specific nitric oxide synthase inhibitor N(G)-monomethyl-L-arginine. These data reveal a clear-cut difference between human melanoma cell lines and cultured normal human melanocytes with respect to inducible nitric oxide synthase inducibility. Although the data do not support the hypothesis that inducible nitric oxide synthase is an important regulator for apoptosis in human melanoma cells, the regulation deficiency found for melanoma cells may be of importance for melanocytic transformation and tumor progression.


Subject(s)
Antineoplastic Agents/pharmacology , Interferon-gamma/pharmacology , Melanocytes/enzymology , Melanoma , Nitric Oxide Synthase/genetics , Tumor Necrosis Factor-alpha/pharmacology , Apoptosis/drug effects , Apoptosis/physiology , Breast Neoplasms , Enzyme Inhibitors/pharmacology , Gene Expression Regulation, Enzymologic/drug effects , Humans , Lipopolysaccharides/pharmacology , Melanocytes/cytology , Nitrates/metabolism , Nitric Oxide Synthase/antagonists & inhibitors , Nitric Oxide Synthase Type II , RNA, Messenger/analysis , Tumor Cells, Cultured/cytology , Tumor Cells, Cultured/enzymology , omega-N-Methylarginine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...